Investors Face August 3 Deadline in GeneDx Securities Fraud Lawsuit

The complaint filed by Schall Brown & Schwartz LLP alleges that GeneDx misled the market through false statements regarding its financial health. The core of the dispute centers on the company’s Q1 2026 earnings report released on May 4, 2026. During this disclosure, GeneDx revealed a contraction in adjusted gross margins, lowered its earnings projections, and recorded a $31.3 million impairment charge linked to Fabric Genomics. Investors claim these revelations exposed the inaccuracy of previous public disclosures, resulting in significant financial losses for shareholders.

Those seeking to participate in the litigation or serve as a representative party are encouraged to contact attorneys Brian Schall or David Schwartz in Los Angeles. While the class has not yet been formally certified, shareholders who choose not to take action remain absent class members. The firm emphasizes that investors may seek recovery for losses incurred during the specified period without bearing any out-of-pocket legal fees or costs.